Published in Gene Therapy Weekly, October 19th, 2000
Failure of radiation therapy is usually detected through blood tests showing increasing levels of prostate-specific antigen (PSA), an indication of prostate cancer activity. Of the first six patients enrolled in this trial, all with rising PSA levels at the time they entered the trial, two have slowed or stopped their increase in serum PSA levels.
Treatments with Leuvectin also appear to be safe and well-tolerated, with no serious...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.